A CD24+CD271+ melanoma cancer stem cell possesses hybrid characteristics of its single marker counterparts and promotes invasion and therapeutic resistance

Abstract Background An important role for phenotype switching has been demonstrated in metastasis and therapeutic resistance of both melanoma and epithelial tumours. Phenotype switching in epithelial tumours is driven by a minority cancer stem cell (CSC) sub-population with lineage plasticity, but s...

Full description

Saved in:
Bibliographic Details
Main Authors: Olivia Knowles, Patricio Doldan, Isabella Hillier-Richardson, Sophia Lunetto, Stephanie Lunt, Gehad Youssef, Luke Gammon, Ian C. Mackenzie, Michael P. Philpott, Hasan Rizvi, Daniele Bergamaschi, Catherine A. Harwood, Adrian Biddle
Format: Article
Language:English
Published: BMC 2025-08-01
Series:BMC Biology
Subjects:
Online Access:https://doi.org/10.1186/s12915-025-02336-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849331668963295232
author Olivia Knowles
Patricio Doldan
Isabella Hillier-Richardson
Sophia Lunetto
Stephanie Lunt
Gehad Youssef
Luke Gammon
Ian C. Mackenzie
Michael P. Philpott
Hasan Rizvi
Daniele Bergamaschi
Catherine A. Harwood
Adrian Biddle
author_facet Olivia Knowles
Patricio Doldan
Isabella Hillier-Richardson
Sophia Lunetto
Stephanie Lunt
Gehad Youssef
Luke Gammon
Ian C. Mackenzie
Michael P. Philpott
Hasan Rizvi
Daniele Bergamaschi
Catherine A. Harwood
Adrian Biddle
author_sort Olivia Knowles
collection DOAJ
description Abstract Background An important role for phenotype switching has been demonstrated in metastasis and therapeutic resistance of both melanoma and epithelial tumours. Phenotype switching in epithelial tumours is driven by a minority cancer stem cell (CSC) sub-population with lineage plasticity, but such a sub-population has not been identified in melanoma. We investigated whether cell surface markers used to identify CSCs in epithelial tumours could identify a CSC sub-population with lineage plasticity in melanoma. Results We identified a CD24+CD271+ minority sub-population in melanoma that possesses the stem cell characteristics of lineage plasticity and self-renewal. This population displayed hybrid characteristics, combining the attributes of discrete CD24+CD271- and CD24-CD271+ cellular sub-populations but with heightened sphere formation, lineage plasticity, migratory ability and drug resistance over its single-marker counterparts. CD24+CD271- and CD24+CD271+ stem cell sub-populations were observed in 10% of human melanomas, mainly at the invasive front. They were also found in human tumour scRNAseq datasets, where they expressed genes associated with stem cells and therapeutic resistance. The CD24-CD271+ sub-population, on the other hand, shared expression of epithelial-mesenchymal transition (EMT) genes with the CD24+CD271+ sub-population. Conclusions The lack of CD24+CD271- and CD24+CD271+ stem cells in the majority of human melanoma specimens led us to conclude that they may be dispensable for melanoma progression. Nevertheless, the enhanced sphere formation, lineage plasticity, migratory ability and drug resistance of the CD24+CD271+ sub-population may signal a contextual requirement for these stem cells when melanomas face challenging environments both clinically and in experimental systems.
format Article
id doaj-art-2c22f5e5ca4d42dcb70b2eca4e865284
institution Kabale University
issn 1741-7007
language English
publishDate 2025-08-01
publisher BMC
record_format Article
series BMC Biology
spelling doaj-art-2c22f5e5ca4d42dcb70b2eca4e8652842025-08-20T03:46:27ZengBMCBMC Biology1741-70072025-08-0123111510.1186/s12915-025-02336-2A CD24+CD271+ melanoma cancer stem cell possesses hybrid characteristics of its single marker counterparts and promotes invasion and therapeutic resistanceOlivia Knowles0Patricio Doldan1Isabella Hillier-Richardson2Sophia Lunetto3Stephanie Lunt4Gehad Youssef5Luke Gammon6Ian C. Mackenzie7Michael P. Philpott8Hasan Rizvi9Daniele Bergamaschi10Catherine A. Harwood11Adrian Biddle12Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of LondonCentre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of LondonCentre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of LondonCentre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of LondonCentre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of LondonCentre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of LondonCentre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of LondonCentre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of LondonCentre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of LondonDepartment of Cellular Pathology, Barts Health NHS TrustCentre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of LondonCentre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of LondonCentre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of LondonAbstract Background An important role for phenotype switching has been demonstrated in metastasis and therapeutic resistance of both melanoma and epithelial tumours. Phenotype switching in epithelial tumours is driven by a minority cancer stem cell (CSC) sub-population with lineage plasticity, but such a sub-population has not been identified in melanoma. We investigated whether cell surface markers used to identify CSCs in epithelial tumours could identify a CSC sub-population with lineage plasticity in melanoma. Results We identified a CD24+CD271+ minority sub-population in melanoma that possesses the stem cell characteristics of lineage plasticity and self-renewal. This population displayed hybrid characteristics, combining the attributes of discrete CD24+CD271- and CD24-CD271+ cellular sub-populations but with heightened sphere formation, lineage plasticity, migratory ability and drug resistance over its single-marker counterparts. CD24+CD271- and CD24+CD271+ stem cell sub-populations were observed in 10% of human melanomas, mainly at the invasive front. They were also found in human tumour scRNAseq datasets, where they expressed genes associated with stem cells and therapeutic resistance. The CD24-CD271+ sub-population, on the other hand, shared expression of epithelial-mesenchymal transition (EMT) genes with the CD24+CD271+ sub-population. Conclusions The lack of CD24+CD271- and CD24+CD271+ stem cells in the majority of human melanoma specimens led us to conclude that they may be dispensable for melanoma progression. Nevertheless, the enhanced sphere formation, lineage plasticity, migratory ability and drug resistance of the CD24+CD271+ sub-population may signal a contextual requirement for these stem cells when melanomas face challenging environments both clinically and in experimental systems.https://doi.org/10.1186/s12915-025-02336-2MelanomaCancer stem cellsCD24Therapy resistance
spellingShingle Olivia Knowles
Patricio Doldan
Isabella Hillier-Richardson
Sophia Lunetto
Stephanie Lunt
Gehad Youssef
Luke Gammon
Ian C. Mackenzie
Michael P. Philpott
Hasan Rizvi
Daniele Bergamaschi
Catherine A. Harwood
Adrian Biddle
A CD24+CD271+ melanoma cancer stem cell possesses hybrid characteristics of its single marker counterparts and promotes invasion and therapeutic resistance
BMC Biology
Melanoma
Cancer stem cells
CD24
Therapy resistance
title A CD24+CD271+ melanoma cancer stem cell possesses hybrid characteristics of its single marker counterparts and promotes invasion and therapeutic resistance
title_full A CD24+CD271+ melanoma cancer stem cell possesses hybrid characteristics of its single marker counterparts and promotes invasion and therapeutic resistance
title_fullStr A CD24+CD271+ melanoma cancer stem cell possesses hybrid characteristics of its single marker counterparts and promotes invasion and therapeutic resistance
title_full_unstemmed A CD24+CD271+ melanoma cancer stem cell possesses hybrid characteristics of its single marker counterparts and promotes invasion and therapeutic resistance
title_short A CD24+CD271+ melanoma cancer stem cell possesses hybrid characteristics of its single marker counterparts and promotes invasion and therapeutic resistance
title_sort cd24 cd271 melanoma cancer stem cell possesses hybrid characteristics of its single marker counterparts and promotes invasion and therapeutic resistance
topic Melanoma
Cancer stem cells
CD24
Therapy resistance
url https://doi.org/10.1186/s12915-025-02336-2
work_keys_str_mv AT oliviaknowles acd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT patriciodoldan acd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT isabellahillierrichardson acd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT sophialunetto acd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT stephanielunt acd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT gehadyoussef acd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT lukegammon acd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT iancmackenzie acd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT michaelpphilpott acd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT hasanrizvi acd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT danielebergamaschi acd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT catherineaharwood acd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT adrianbiddle acd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT oliviaknowles cd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT patriciodoldan cd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT isabellahillierrichardson cd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT sophialunetto cd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT stephanielunt cd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT gehadyoussef cd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT lukegammon cd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT iancmackenzie cd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT michaelpphilpott cd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT hasanrizvi cd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT danielebergamaschi cd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT catherineaharwood cd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance
AT adrianbiddle cd24cd271melanomacancerstemcellpossesseshybridcharacteristicsofitssinglemarkercounterpartsandpromotesinvasionandtherapeuticresistance